dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
Company profile
Ticker
ALDX
Exchange
Website
CEO
Todd C. Brady
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Aldexa Therapeutics, Inc., Neuron Systems Inc
SEC CIK
Corporate docs
Subsidiaries
Helio Vision, LLC • Helio Vision Germany GmbH ...
ALDX stock data
Latest filings (excl ownership)
8-K
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
28 Mar 24
S-3
Shelf registration
7 Mar 24
S-8
Registration of securities for employees
7 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Regulation FD Disclosure
13 Feb 24
8-K
Other Events
4 Jan 24
8-K
Other Events
21 Dec 23
8-K
Regulation FD Disclosure
19 Dec 23
8-K
Regulation FD Disclosure
28 Nov 23
Transcripts
ALDX
Earnings call transcript
2022 Q4
9 Mar 23
ALDX
Earnings call transcript
2022 Q3
10 Nov 22
ALDX
Earnings call transcript
2022 Q2
5 Aug 22
ALDX
Earnings call transcript
2022 Q1
5 May 22
ALDX
Earnings call transcript
2021 Q4
17 Mar 22
ALDX
Earnings call transcript
2021 Q3
28 Oct 21
ALDX
Earnings call transcript
2021 Q2
5 Aug 21
ALDX
Earnings call transcript
2021 Q1
6 May 21
ALDX
Earnings call transcript
2020 Q4
11 Mar 21
ALDX
Earnings call transcript
2020 Q3
5 Nov 20
Latest ownership filings
4/A
Stephen Machatha
17 Apr 24
4/A
Bruce Greenberg
17 Apr 24
4
JOSEPH EDELMAN
8 Apr 24
4
JOSEPH EDELMAN
3 Apr 24
4
Bruce Greenberg
12 Mar 24
4
Stephen Machatha
12 Mar 24
4
Todd C Brady
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 143.33 mm | 143.33 mm | 143.33 mm | 143.33 mm | 143.33 mm | 143.33 mm |
Cash burn (monthly) | 2.78 mm | (no burn) | 3.18 mm | 4.20 mm | 2.67 mm | 3.50 mm |
Cash used (since last report) | 18.51 mm | n/a | 21.20 mm | 27.96 mm | 17.81 mm | 23.34 mm |
Cash remaining | 124.82 mm | n/a | 122.14 mm | 115.37 mm | 125.52 mm | 120.00 mm |
Runway (months of cash) | 44.9 | n/a | 38.4 | 27.5 | 46.9 | 34.2 |
Institutional ownership, Q3 2023
64.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 119 |
Opened positions | 16 |
Closed positions | 14 |
Increased positions | 41 |
Reduced positions | 36 |
13F shares | Current |
---|---|
Total value | 250.31 bn |
Total shares | 37.77 mm |
Total puts | 213.30 k |
Total calls | 141.70 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Perceptive Advisors | 11.35 mm | $75.82 bn |
BLK Blackrock | 3.37 mm | $22.52 bn |
Vanguard | 3.19 mm | $21.29 bn |
STT State Street | 3.07 mm | $20.48 bn |
Knoll Capital Management | 3.03 mm | $20.25 bn |
Dimensional Fund Advisors | 1.21 mm | $8.05 bn |
Laurion Capital Management | 1.13 mm | $7.54 bn |
Eagle Asset Management | 1.04 mm | $6.96 bn |
Geode Capital Management | 975.57 k | $6.52 bn |
Verition Fund Management | 935.27 k | $6.25 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Perceptive Advisors | Common Stock | Buy | Acquire P | Yes | No | 4.74 | 37,712 | 178.75 k | 9,275,851 |
4 Apr 24 | Perceptive Advisors | Common Stock | Buy | Acquire P | Yes | No | 4.67 | 140,281 | 655.11 k | 9,238,139 |
3 Apr 24 | Perceptive Advisors | Common Stock | Buy | Acquire P | Yes | No | 4.09 | 309,847 | 1.27 mm | 9,097,858 |
2 Apr 24 | Perceptive Advisors | Common Stock | Buy | Acquire P | Yes | No | 3.44 | 186,051 | 640.02 k | 8,788,011 |
1 Apr 24 | Perceptive Advisors | Common Stock | Buy | Acquire P | Yes | No | 3.25 | 8,374 | 27.22 k | 8,601,960 |
12 Mar 24 | Stephen Machatha | Common Stock | Sell | Dispose S | No | No | 3.164 | 11,537 | 36.50 k | 252,812 |
11 Mar 24 | Bruce Greenberg | Common Stock | Sell | Dispose S | No | No | 3.4064 | 13,201 | 44.97 k | 130,154 |
11 Mar 24 | Bruce Greenberg | Common Stock | Sell | Dispose S | No | No | 3.4064 | 13,201 | 44.97 k | 120,699 |
9 Mar 24 | Bruce Greenberg | Stock Option Common Stock | Grant | Acquire A | No | No | 3.62 | 252,280 | 913.25 k | 252,280 |
News
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
4 Apr 24
Oppenheimer Upgrades Aldeyra Therapeutics to Outperform, Announces $10 Price Target
3 Apr 24
HC Wainwright & Co. Reinstates Buy on Aldeyra Therapeutics, Announces $10 Price Target
2 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
5 Mar 24
Press releases
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
18 Apr 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
9 Feb 24
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
6 Feb 24